In the BioHarmony Drug Report Database
Eravacycline
Xerava (eravacycline) is a small molecule pharmaceutical. Eravacycline was first approved as Xerava on 2018-08-27. It is used to treat intraabdominal infections in the USA. It has been approved in Europe to treat bacterial infections and infections. Xerava’s patents are valid until 2030-12-28 (FDA).
Trade Name
|
Xerava |
|---|---|
Common Name
|
eravacycline |
ChEMBL ID
|
CHEMBL1951095 |
Indication
|
bacterial infections, infections, intraabdominal infections |
Drug Class
|
Antibiotics (tetracycline derivatives) |
Image (chem structure or protein)